Core Insights - The current A-share market rally is driven by a combination of policy expectations, industry trends, capital flow, and market sentiment, indicating a complex and critical new phase in the market [1][2] - The influx of incremental capital is a key factor in the ongoing market strength, with significant net inflows from northbound capital and increased trading volumes [2][3] Market Dynamics - The strong market performance is attributed to a multi-dimensional resonance of policies, industry developments, and capital dynamics, with a notable shift from a focus on existing capital to new incremental capital [2][3] - Northbound capital has seen multiple days of net inflows exceeding 10 billion yuan since January, with daily trading volumes rising from 1.7 trillion yuan to over 2.8 trillion yuan [2] Investment Strategies - Private equity firms are actively adjusting their portfolios, focusing on both offensive and defensive strategies, with a clear emphasis on sectors like AI and cyclical industries [4][5] - Investment in technology sectors is expanding from hardware to applications, with a focus on areas such as innovative pharmaceuticals, brain-computer interfaces, and commercial aerospace [4][5] Sector Focus - High-growth sectors such as AI applications, commercial aerospace, innovative pharmaceuticals, and non-ferrous metals are repeatedly highlighted as key investment areas [6][7] - There is a growing interest in cyclical assets due to expectations of economic recovery, with private equity firms increasing their holdings in sectors like non-ferrous metals and chemicals [5][6] Investor Sentiment - Institutional investors maintain a strategic optimism, while individual investors exhibit anxiety and indecision, reflecting a dichotomy in market sentiment [4][8] - Recommendations for individual investors emphasize the importance of professional management, focusing on long-term trends, and utilizing standardized investment tools to mitigate selection difficulties [8][9] Conclusion - The current market environment presents a comprehensive test of cognitive depth, strategic flexibility, and investment discipline, with private equity firms adapting their strategies to navigate the complexities of the evolving market landscape [9]

Group 1 - The A-share market has seen strong performance in sectors such as commercial aerospace, brain-computer interfaces, storage chips, controllable nuclear fusion, and photolithography [1][2] - Institutional investors have been actively researching popular concepts since the beginning of 2026, indicating a strong desire to capitalize on the spring market [1][4] - Companies like Entropy Technology, which focuses on brain-computer interfaces, have attracted significant attention, with over 100 institutions participating in their research activities [1][2] Group 2 - Superjet Co., involved in commercial aerospace, has also garnered attention, with three research sessions attracting over 100 institutions, including 43 public funds [2] - Guanglian Aviation, a leading private enterprise in aerospace equipment, has participated in two research sessions with 79 institutions, focusing on national projects [2] - Companies like Dineike, which specializes in smart home and medical devices, have also attracted interest from dozens of institutions regarding their brainwave interaction technology [3] Group 3 - Many stocks associated with popular concepts have seen significant price increases, with Superjet Co., Hualing Cable, and Guanglian Aviation all rising over 120% since December 2025 [4] - Institutional research activity has been high, with 155 public institutions participating in A-share research in December 2025, covering 451 stocks [4] - The technology sector is viewed as the core theme for the A-share market in 2026, with artificial intelligence being a leading area of growth [4][5]

Core Insights - Tianjin Economic and Technological Development Zone has released the "Future Industry Cultivation and Development Action Plan (2025-2027)" aiming to establish a "4+2+X" future industry layout by 2027, focusing on key technologies, products, applications, talent, and competitive enterprises in future industries [1][2] Group 1: Future Industry Development Strategy - The action plan aims to create a world-class future industry ecosystem, emphasizing "future-oriented advantages" and "industrialization of future technologies" as the two main lines of development [1] - The "4+2+X" future industry development system will focus on four cornerstone tracks: nucleic acid drugs, biomanufacturing, general artificial intelligence, and basic and key materials [1] - The plan also includes two cutting-edge tracks: embodied intelligence and automotive-grade chips, along with several potential tracks such as future healthcare, nano-manufacturing, and software-defined interconnect chips [1] Group 2: Implementation Actions - To achieve the development goals, the Tianjin Economic and Technological Development Zone will focus on a complete innovation ecosystem, implementing ten key actions including technology innovation source actions and future enterprise cultivation actions [2] - The technology innovation source action will concentrate on building high-level innovation platforms, aiming for 1 to 3 key source platforms for each track [2]

投资者： 请问截止12月31日公司股东人数是多少？ 董秘： 您好，公司2025年12月31日股东人数及其详情请关注并查阅公司定期报告披露的相关内容，感 谢关注！ 投资者： 尊敬的董秘您好，贵公司2026年1月5日发布的解押公告披露的质押起始日期的质押在2023年 的公告中已解除，请问2026年1月5日发布的解押公告中解除的是否对应的是质押到期日为2028年5月17 日的质押记录？ 董秘： 您好，关于公司控股股东部分股份解除质押的事项已于2026年1月5日披露于证监会指定的信息 披露网站，详见《关于公司控股股东部分股份解除质押的公告》（2026-03），谢谢！ 投资者： 公司股票5年间从最高价（231元）算起，5年跌幅超90%。按照创业板有关规定，股票如果下 跌异常，要向投资者发布退市风险警示提醒。公司是否达到了退市风险警示的提示要求，还是会等到跌 到退市时才会发布退市风险警示公告呢？！ 董秘： 您好，公司严格按照法律法规履行信息披露义务。公司持续优化经营策略，加速推进自研产品 上市，强化市场宣传推广，促进公司稳健发展，谢谢！ 截至2026年1月9日收盘，智飞生物(300122)报收于19.8元，上涨1.69% ...

截至2026年1月9日收盘，佐力药业(300181)报收于16.6元，上涨0.85%，换手率2.18%，成交量13.17万 手，成交额2.17亿元。 董秘最新回复 来自交易信息汇总：1月9日主力资金净流出2815.54万元，游资与散户资金分别净流入1075.85万元 和1739.69万元。 交易信息汇总资金流向 1月9日主力资金净流出2815.54万元；游资资金净流入1075.85万元；散户资金净流入1739.69万元。 投资者： 未来社会是智能化的社会，脑机智能将会占据重要地位，请问贵司对这个方向有哪些战略规 划和储备，谢谢！ 董秘： 您好！公司暂未布局脑机接口领域。感谢您的关注！ 投资者： 近段时间，公司股价与大势背离走，下跌又多，是否公司2025年业绩不达标，没有完成激励 指标？ 董秘： 您好！股价波动受宏观环境及市场情绪等多重因素综合影响，公司将持续做好经营，努力提升 经营效益，切实维护好广大投资者权益和资本市场稳定。感谢您对公司的关注！ 当日关注点 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Viewpoint - The current "brain-computer interface" is a market hotspot, attracting significant investor attention, particularly after the company's stock price rose by 6.52% with a trading volume increase of 299% compared to the previous trading day. The company is urged to ensure that disclosures related to this hot topic are accurate and complete to avoid misleading investors [2] Group 1: Regulatory Actions - The Shanghai Stock Exchange issued a regulatory warning to the company, highlighting inconsistencies in the announcement regarding the technical path of its partner and insufficient risk disclosures related to collaboration uncertainties [2] - Following the announcement of a strategic cooperation framework agreement with Shenzhen Brain Machine Starlink Technology Co., Ltd., the company faced immediate media scrutiny and market attention [2][3] Group 2: Partnership Details - The company clarified that the current research products of Brain Machine Starlink are based on a non-invasive technical path, with no invasive technology in development, and that some products are still in early research or pre-clinical stages [3] - The company plans to invest no more than 15 million yuan in Brain Machine Starlink, with an estimated research and development investment of around 30 million yuan for the related projects, which are still in early stages and have uncertain development timelines [3] Group 3: Financial Performance - For the first three quarters of 2025, the company's revenue was approximately 1.287 billion yuan, a year-on-year decrease of 7.69%, while net profit was about 60.42 million yuan, down 72.36% year-on-year. The company reported cash and cash equivalents of 465 million yuan [4]

板块热度飙升 Wind数据显示，上周，万得脑机接口概念指数（8841700）大涨18.95%。相关概念股中，创新医疗收获 涨停五连板，南京熊猫、普利特分别录得涨停四连板，美好医疗、三博脑科等也连续4个交易日大涨。 脑机接口板块大涨的背后，是政策、技术、产业与资本的多重利好叠加释放。 2026年开年，脑机接口一跃成为全球科技与资本市场的焦点之一。 近日，特斯拉CEO马斯克宣布，旗下Neuralink公司将于2026年启动脑机接口设备的"大规模生产"，并将 转向"更加精简和几乎完全自动化的外科手术流程"，这一表态也迅速点燃了市场热情。几乎前后脚，国 内脑机接口独角兽企业强脑科技宣布完成了约20亿元融资，规模位居全球第二。 在海外量产预期、国内政策支持与临床突破的多重共振下，A股脑机接口板块掀起了涨停潮。在板块大 涨的这波行情中，提前埋伏其中的基金也明显受益，净值大幅攀升。 脑机接口，这个一度只存在于科幻作品中的概念，正加速走进现实。 政策、技术与资本共振 1月5日，华银健康生活主题灵活配置单日涨幅达11.8%，领跑全市场基金；长城消费增值混合、国泰创 新医疗混合等单日涨幅也超过10%，位居市场前十。根据2025年 ...

Group 1 - Public funds have entered the market with over 45 billion yuan expected by January 10, 2026, driven by new stock ETFs and active funds [1] - The total scale of newly listed stock ETFs is 6.345 billion yuan, while active funds nearing 40 billion yuan are in the accumulation phase [1] - Individual investors are leading the ETF market, with some products having over 90% share from personal investors [1] Group 2 - Over 100 billion yuan flowed into the market through ETFs last week, with a total trading volume of 14.13 trillion yuan in the Shanghai and Shenzhen markets [2] - Stock-type and cross-border ETFs saw a net inflow of 13.14 billion yuan, while broad-based index ETFs experienced a net outflow of 12.9 billion yuan [2] Group 3 - China has submitted applications for an additional 203,000 satellites, primarily from a new agency, the Radio Innovation Institute [3] - The increase in satellite launches is expected to accelerate in 2026, with private commercial rocket companies likely to play a significant role [3] Group 4 - A number of brain-computer interface concept stocks have been heavily researched by institutions, with Entropy Technology receiving the highest number of visits at 136 [4] - Other notable companies include Prilite and Xiangyu Medical, with 127 and 71 institutional visits respectively [4] Group 5 - Shaoyang Hydraulic's stock price surged by 106% over 11 trading days, closing at 58.45 yuan with a market capitalization of 6.367 billion yuan [5][8] Group 6 - In 2025, 89.74% of 9,934 private equity securities products achieved positive returns, with an average return rate of 25.68% [9] - Quantitative long strategies performed exceptionally well, with a 95.81% positive return rate and an average return of 39.51% [9] Group 7 - Tianpu Co. is under investigation by the China Securities Regulatory Commission due to abnormal stock trading, but the company states that its operations remain normal [10] Group 8 - This week, 23 stocks are facing unlocks, with a total market value exceeding 48 billion yuan, including over 10 billion yuan from Zhongke Lanyun [11]

Investment Rating - The report maintains a "Buy" rating for the pharmaceutical and biotechnology industry, specifically recommending stocks such as Micro-Invasive Brain Science, Xiangyu Medical, and Meihua Medical [1]. Core Insights - The report emphasizes the focus on brain-computer interfaces (BCI) as a strategic high ground in global technology, supported by national policies and significant investments [5][19]. - It highlights the approval of innovative drugs and therapies, such as the human thyroid-stimulating hormone beta and the HER2-targeted therapies, which are expected to set new standards in treatment [2][3]. - The report ranks sub-industries in terms of investment potential, with innovative drugs at the top, followed by research services, CXO, traditional Chinese medicine, medical devices, and pharmacies [3][12]. Summary by Sections Industry Trends - The A-share pharmaceutical index has increased by 7.81% year-to-date, outperforming the CSI 300 by 5.03% [11]. - The report notes a significant rise in the healthcare sector, with medical services and devices showing strong performance [11]. Policy Support for Brain-Computer Interfaces - The "14th Five-Year Plan" identifies brain-computer interfaces as a key future industry, with a clear policy support from the government [18]. - The National Health Insurance Administration has established pricing standards for BCI procedures, indicating a commitment to support this emerging field [19][20]. R&D Progress and Company Dynamics - The report lists several companies with promising drug pipelines, including those focusing on PD1 PLUS, ADC, and small nucleic acids, suggesting specific stocks to watch [14]. - It provides a detailed overview of recent approvals and clinical trials, indicating a robust pipeline for innovative therapies [2][3]. Market Performance - The report highlights the significant gains in the pharmaceutical sector, with specific stocks like Innovation Medical and Sanbo Brain Science showing remarkable increases [11]. - It also notes the performance of H-shares, with companies like Jinfang Pharmaceutical-B and Shengnuo Pharmaceutical-B leading the gains [11].

Company Overview - Aipeng Medical focuses on medical devices, specializing in pain management and upper airway management, while also exploring brain-computer interface innovations [5] - The company has a strategic partnership with Ruishen'an Medical, a leading player in the neuroregulation field in China [5] Product Competitiveness - The "Multimodal ADHD Behavioral Training System" integrates data connectivity between in-hospital and home training environments, addressing both medication and behavioral training as primary treatment options [6] - The system aims to provide a comprehensive training solution, mitigating risks associated with traditional single behavioral training products [6] Clinical Applications - The Persistent Insomnia Anesthesia Treatment System has been implemented in hospitals, showing promising treatment outcomes and attracting interest from sleep and anesthesia specialists [7] - The company’s EEG collection products are essential components of the ADHD treatment system, with relevant pricing established in various provinces [9] Future Investments - Aipeng Medical plans to continue exploring brain-computer interface opportunities aligned with its strategic direction, focusing on sensor technology, signal processing, and clinical applications for mental health disorders [10] - The establishment of an AI and Brain-Computer Engineering Research Institute aims to drive innovation in pain management, anesthesia, and mental health diagnostics [10] Business Progress of Ruishen'an - Ruishen'an has successfully launched several products, including the implantable vagus nerve stimulator and the rechargeable spinal cord stimulator, generating revenue [11] - The first domestic implantation of a closed-loop neurostimulation system for Parkinson's disease is expected to occur by the end of 2025, marking a significant advancement in clinical practice [11]